BioWorld

May 16, 2006

AstraZeneca Buying CAT, Giving Valuation Of $1.3B

LONDON - AstraZeneca plc is buying Cambridge Antibody Technology (CAT) Group plc, the UK's largest biotech, in an agreed cash deal that will cost AstraZeneca £567 million, and values CAT at £702 million (US$1.3 billion). (BioWorld Today) Read More

Clinical Data Spins Off Precigen To Continue Phase III Research

Marshall Edwards Licenses Two Oncology Compounds

Congresswoman Calls For More FDA Power On Phase IV Studies

Clinic Roundup

U.S. Patent Disclosures

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...